In vivo model mimicking natural history of dog prostate cancer using DPC-1, a new canine prostate carcinoma cell line

Anidjar, Maurice; Villette, Jean‐Marie; Devauchelle, Patrick; Delisle, F.; Cotard, J.-P.; Billotey, Claire; Cochand‐Priollet, Béatrix; Copin, Henri; Barnoux, Muriel; Triballeau, Sylvie; Rain, J. D.; Fiet, Jean; Teillac, P.; Berthon, Philippe; Cussenot, Olivier

doi:10.1002/1097-0045(200101)46:1<2::aid-pros1002>3.0.co;2-5

Cited by 38 publications

(23 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently the canine prostate allograft model has been reported in evaluation of histotripsy focal ablation for localized PCa (42). While a variety of canine prostate carcinoma cell lines as xenografts, including CPA-1, DPC-1, Ace-1, Leo and so on, have proved to be highly tumorigenic in nude mice; only DPC-1 and Ace-1 have been successfully used in the development of canine PCa allograft models (43-45). DPC-1 cell line was established from an 11-year-old male Doberman Pinscher that presented a large poorly differentiated prostatic adenocarcinoma with bilateral iliac lymphadenopathy (43); whereas the Ace-1 cell line was derived from an 8-year-old male castrated Labrador Retriever (42).…”

Section: Canine Orthotopic Pca Modelsmentioning

confidence: 99%

“…While a variety of canine prostate carcinoma cell lines as xenografts, including CPA-1, DPC-1, Ace-1, Leo and so on, have proved to be highly tumorigenic in nude mice; only DPC-1 and Ace-1 have been successfully used in the development of canine PCa allograft models (43-45). DPC-1 cell line was established from an 11-year-old male Doberman Pinscher that presented a large poorly differentiated prostatic adenocarcinoma with bilateral iliac lymphadenopathy (43); whereas the Ace-1 cell line was derived from an 8-year-old male castrated Labrador Retriever (42). Both allograft models demonstrated promising relevant features, such as intraprostatic growth of tumors, development of regional lymph nodes, and distant metastases (43-45).…”

Section: Canine Orthotopic Pca Modelsmentioning

confidence: 99%

See 1 more Smart Citation

Canine prostate models in preclinical studies of minimally invasive interventions: part I, canine prostate anatomy and prostate cancer models

Sun¹,

Báez-Díaz²,

Sánchez‐Margallo³

2017

Transl. Androl. Urol.

View full text Add to dashboard Cite

The high prevalence of prostate cancer (PCa) in elderly men and technical advances in early detection of localized PCa have led to continued efforts to develop new therapeutic options of minimally invasive nature in current urologic oncology community. Increasing newly emerging therapies are undergoing preclinical tests on the technical feasibility, efficacy and safety in animal experiments. The dog is an ideal large animal because of its similar anatomy to human and the capability allowing the use of the same medical devices applied in future clinical trials. Awareness of the local anatomy, microvascular structure, and histological features of the prostate in dogs is essential to experimental design and performance of the tested procedures and techniques. Although dogs with spontaneous PCa may be used in preclinical investigation, the low incidence and pathological features limit its utility. Alternatively, canine orthotopic PCa models have a great potential in preclinical research for this purpose. The goal of this review is to provide detailed anatomic and histological information of the canine prostate, outline the pathological and clinical characteristics of spontaneous PCa in dogs and discuss the current status of canine orthotopic PCa models.

show abstract

Section: Canine Orthotopic Pca Modelsmentioning

confidence: 99%

Section: Canine Orthotopic Pca Modelsmentioning

confidence: 99%

Canine prostate models in preclinical studies of minimally invasive interventions: part I, canine prostate anatomy and prostate cancer models

Sun¹,

Báez-Díaz²,

Sánchez‐Margallo³

2017

Transl. Androl. Urol.

View full text Add to dashboard Cite

show abstract

“…4 They have been used for subcutaneous xenografts in mice and an orthotopic allograft model in immunosuppressed dogs. The subcutaneous xenografts did not develop metastases; however, the canine orthotopic model did result in mixed osteoblastic/osteolytic metastases in the pelvic bones in 2 of 12 dogs.…”

Section: Animal Modelsmentioning

confidence: 99%

Animal Models of Bone Metastasis

et al. 2015

View full text Add to dashboard Cite

Bone is one of the most common sites of cancer metastasis in humans and is a significant source of morbidity and mortality. Bone metastases are considered incurable and result in pain, pathologic fracture, and decreased quality of life. Animal models of skeletal metastases are essential to improve the understanding of the molecular pathways of cancer metastasis and growth in bone and to develop new therapies to inhibit and prevent bone metastases. The ideal animal model should be clinically relevant, reproducible, and representative of human disease. Currently, an ideal model does not exist; however, understanding the strengths and weaknesses of the available models will lead to proper study design and successful cancer research. This review provides an overview of the current in vivo animal models used in the study of skeletal metastases or local tumor invasion into bone and focuses on mammary and prostate cancer, lymphoma, multiple myeloma, head and neck squamous cell carcinoma, and miscellaneous tumors that metastasize to bone.

show abstract

“…In dogs, nearly all prostate cancers are androgen-independent, and thus, we expected that prostate cancer cell lines derived from dog e.g. DPC-1 [27], ACe-1 [28], and Leo [29] may downregulate the expression of REIC/Dkk-3.…”

Section: Discussionmentioning

confidence: 99%

Canine REIC/Dkk-3 interacts with SGTA and restores androgen receptor signalling in androgen-independent prostate cancer cell lines

et al. 2017

View full text Add to dashboard Cite

BackgroundThe pathological condition of canine prostate cancer resembles that of human androgen-independent prostate cancer. Both canine and human androgen receptor (AR) signalling are inhibited by overexpression of the dimerized co-chaperone small glutamine-rich tetratricopeptide repeat-containing protein α (SGTA), which is considered to cause the development of androgen-independency. Reduced expression in immortalised cells (REIC/Dkk-3) interferes with SGTA dimerization and rescues AR signalling. This study aimed to assess the effects of REIC/Dkk-3 and SGTA interactions on AR signalling in the canine androgen-independent prostate cancer cell line CHP-1.ResultsMammalian two-hybrid and Halo-tagged pull-down assays showed that canine REIC/Dkk-3 interacted with SGTA and interfered with SGTA dimerization. Additionally, reporter assays revealed that canine REIC/Dkk-3 restored AR signalling in both human and canine androgen-independent prostate cancer cells. Therefore, we confirmed the interaction between canine SGTA and REIC/Dkk-3, as well as their role in AR signalling.ConclusionsOur results suggest that this interaction might contribute to the development of a novel strategy for androgen-independent prostate cancer treatment. Moreover, we established the canine androgen-independent prostate cancer model as a suitable animal model for the study of this type of treatment-refractory human cancer.Electronic supplementary materialThe online version of this article (doi:10.1186/s12917-017-1094-4) contains supplementary material, which is available to authorized users.

show abstract

In vivo model mimicking natural history of dog prostate cancer using DPC-1, a new canine prostate carcinoma cell line

Cited by 38 publications

References 12 publications

Canine prostate models in preclinical studies of minimally invasive interventions: part I, canine prostate anatomy and prostate cancer models

Canine prostate models in preclinical studies of minimally invasive interventions: part I, canine prostate anatomy and prostate cancer models

Animal Models of Bone Metastasis

Canine REIC/Dkk-3 interacts with SGTA and restores androgen receptor signalling in androgen-independent prostate cancer cell lines

Contact Info

Product

Resources

About